Nephro Trial Files: Peer Mentorship in Hemodialysis Patients, Everolimus for Kidney Transplant Recipients, and Video-Assisted Electronic Consent for PKB
Effect of Peer Mentorship on Hospitalizations among Patients Receiving Maintenance Hemodialysis
Golestaneh L et al. JASN (April 2025)
Bottom Line: This multi-center, pragmatic, randomized, controlled trial evaluated the effectiveness of peer mentorship to reduce hospitalization rates among patients receiving hemodialysis. A total of 200 participants were enrolled, with 101 receiving the peer-mentor intervention and 99 receiving usual care over a 3-month period. The primary outcome was monthly counts of unplanned hospitalizations and ED visits, with the intervention group showing an adjusted incidence rate ratio (aIRR) of 0.60 (95% CI 0.47, 0.76) compared to 0.85 (95% CI 0.64, 1.15) for the comparator group. While the overall results did not show significant reductions, effectiveness was suggested in certain subgroups.
Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity
Messchendorp AL et al. Clinical Infectious Diseases (April 2025)
Bottom Line: This randomized clinical trial evaluated the impact of replacing mycophenolate mofetil (MMF) with everolimus on vaccine immunogenicity in kidney transplant recipients (KTRs) over a duration of six weeks. A total of 110 KTRs received a COVID-19 booster and herpes zoster vaccinations. The primary outcome, neutralizing antibody response, was assessed 28 days post-vaccination, revealing comparable results for COVID-19 antibodies (308 vs 327) but enhanced humoral response for herpes zoster with everolimus (2192 vs 1101). Safety outcomes indicated a higher incidence of bacterial infections with everolimus (27.3% vs 11.1%). The study concluded that while everolimus may improve vaccine responses, its timing and risks require careful consideration.
A Randomized Controlled Trial of Video-Assisted Electronic Consent Versus Standard Consent for Percutaneous Kidney Biopsy
Gois PHF et al. CJASN (April 2025)
Bottom Line: This single-center, open-label, randomized controlled trial assessed the benefits of video-assisted electronic consent (eConsent) versus usual consent practices for percutaneous kidney biopsies (PKB). Conducted from July 2021 to January 2024, 120 patients were randomized (60 in each group). The primary outcome was questionnaire-based patient comprehension, with the eConsent group answering on average three more questions correctly out of nine compared to the control group (p<0.001). No significant differences were observed in patient-reported experience, anxiety, or satisfaction between groups. The study concluded that video-assisted eConsent improves patient comprehension without affecting overall experience.
Nephro Trial Files Issue #NPH-2025-10
Want to view past issues? Visit our archive:
